Catto - Figure 24
Low risk NMI: Death
FIG. 24: The results reported from our institution (Figures 20-23) match those from around the world. As summarized in this Figure, whereas in Sheffield we had a 2.4% rate of disease-specific mortality DSM,[22] in Sweden, it was 2.4% in a roughly similar size cohort,[21] in the United States it was 2.8%,[23] and slightly lower at 1.2% as reported from a multisite study in North America and Europe.[24]
In sum, the risks of death from this NMI urologic cancer are very small, and may be similar to the overall mortality rates in the general population if the results are smoking- and age-adjusted. In other words, these morality rates in patients with low-risk NMI bladder cancer do not support the hypothesis that extensive surveillance of these patients is justified for the costs required.
References
Holmäng S, Hedelin H, Anderström C, et al. Recurrence and progression in low grade papillary urothelial tumors. J Urol. 1999;162:702−7
Linton KD, Rosario DJ, Thomas F, et al. Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance. J Urol. 2013;189:828−33 https://doi.org/10.1016/j.juro.2012.09.084
Prout GR Jr, Barton BA, Griffin PP, Friedell GH; National Bladder Cancer Group. Treated history of noninvasive grade 1 transitional cell carcinoma. J Urol. 1992;148:1413−9
Rieken M, Xylinas E, Kluth L, et al. Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder. Eur Urol. 2014;65:201−9 https://doi.org/10.1016/j.eururo.2013.08.034
